Rh-endostatin plus camrelizumab and chemotherapy in first-line treatment of advanced non-small cell lung cancer: A multicenter retrospective study

Abstract

Background: Clinical evidence of immune checkpoint inhibitors combined with antiangiogenic drugs in patients with advanced non-small cell lung cancer (NSCLC) was limited. Recombinant human endostatin (rh-endostatin), an antiangiogenic drug, and camrelizumab, an anti-PD-1 antibody, have been approved for the treatment of advanced NSCLC in China. This study aimed to investigate the efficacy and safety of rh-endostatin plus camrelizumab and chemotherapy in the treatment of advanced NSCLC.

Methods: Eligible patients were enrolled and received camrelizumab (200 mg, day 1) every 3 weeks and continuous intravenous infusion of rh-endostatin (70 mg/day, days 1-3) and cisplatin combined with pemetrexed (for adenocarcinoma) or paclitaxel (for NSCLC other than adenocarcinoma) every 3 weeks. Primary endpoint was progression-free survival (PFS). Secondary endpoints were objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety profiles.

Results: Overall, 27 patients were included, and 25 patients were eligible for efficacy evaluation. For these 25 patients, ORR was 48.15% (13/27) and DCR was 85.19% (23/27). With a median follow-up of 10.37 months, the median PFS was 8.9 (95% CI: 4.23-13.57) months. Median OS was not reached. Overall, 96.3% of patients experienced at least one treatment-related adverse event, and grade 3 TRAEs occurred in 9 (33.3%) patients. No unexpected AEs were observed.

Conclusion: Rh-endostatin plus camrelizumab and chemotherapy showed favorable efficacy and safety profile in patients with advanced NSCLC, representing a promising treatment regimen for these patients.

Keywords: anti-angiogenesis; camrelizumab; immune checkpoint inhibitors; non-small cell lung cancer; recombinant human endostatin.

FIGURE 1

Flowchart of the inclusion and exclusion procedure.

FIGURE 2

Kaplan–Meier curves for (A) progression‐free survival and (B) overall survival (OS) of the whole cohort

FIGURE 3

Kaplan–Meier curves for subgroup analysis of PFS. (A) Age; (B) Sex; (C) ECOG PS; (D) Pathology; (E) PD‐L1 tumor proportion score (TPS); (F) Cycles of rh‐endostatin combined with camrelizumab and chemotherapy treatment; (G) Maintenance treatment.

FIGURE 4

Kaplan–Meier curves for subgroup analysis of OS. (A) Age; (B)Sex; (C) ECOG PS; (D) Pathology; (E) PD‐L1 tumor proportion score (TPS); (F) Cycles of rh‐endostatin combined with camrelizumab and chemotherapy treatment; (G) Maintenance treatment.